Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKANOH)

Drug Name
Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)] Drug Info
Synonyms
Loxiglumide; LOXIGLUMIDE; 107097-80-3; Loxiglumide [INN]; Loxiglumidum [Latin]; Loxiglumida [Spanish]; CR 1505; CR-1505; CHEMBL206025; (+-)-4-(3,4-Dichlorobenzamido)-N-(3-methoxypropyl)-N-pentylglutaramic acid; 4-(3,4-dichlorobenzamido)-5-((3-methoxypropyl)(pentyl)amino)-5-oxopentanoic acid; (+-)-4-((3,4-Dichlorobenzoyl)amino)-5-((3-methoxypropyl)pentylamino)-5-oxopentanoic acid; D,L-4-(3,4-Dichlorobenzoylamino)-5-(N-3-methoxypropylpentylamino)-5-oxo-pentanoic acid; Loxiglumidum; Loxiglumida; Pentanoic
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
60182
ChEBI ID
CHEBI:31785
CAS Number
CAS 107097-80-3
TTD Drug ID
DMKANOH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Neuropeptide Y receptor type 5 (NPY5R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CGP71683A DMRYC08 Obesity 5B81 Discontinued in Phase 3 [5]
Velneperit DMROSHN Obesity 5B81 Discontinued in Phase 2 [6]
S-234462 DM80P4U Obesity 5B81 Discontinued in Phase 1 [6]
Axovan-3 DM1JN6A Eating disorder 6B82 Discontinued in Phase 1 [7]
FR-79620 DMXR287 Diabetic complication 5A2Y Preclinical [8]
GW-594884A DMHUD27 Obesity 5B81 Preclinical [8]
NPY5RA-972 DMXUCSN Obesity 5B81 Preclinical [8]
RWJ-49815 DMUGZMO Fungal infection 1F29-1F2F Terminated [7]
AR-129330 DMUSYKG Discovery agent N.A. Investigative [9]
S-25585 DMBUD1M Eating disorder 6B82 Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cholecystokinin receptor type A (CCKAR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexloxiglumide DM52HUD Pancreatic malfunction DC30-DC3Z Phase 2 [10]
proglumide DM4MF9V Influenza virus infection 1E30-1E32 Phase 2 [11]
Lintitript DMS5X94 Obesity 5B81 Discontinued in Phase 2 [12]
Tarazepide DMX6ZYE Gastrointestinal disease DE2Z Discontinued in Phase 2 [13]
GI 181771 DMIUFS4 Obesity 5B81 Discontinued in Phase 2 [14]
Pranazepide DMP43IR Pancreatic malfunction DC30-DC3Z Discontinued in Phase 2 [15]
CE-326597 DMXO49B Obesity 5B81 Discontinued in Phase 2 [16]
UCL-2000; butabindide DML51D0 Obesity 5B81 Discontinued in Phase 1 [8]
SSR-125180 DMSOBW2 Obesity 5B81 Discontinued in Phase 1 [17]
T-0632 DML4M5K Pancreatic malfunction DC30-DC3Z Discontinued in Phase 1 [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cholecystokinin receptor (CCKR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
A-68552 DM1BDHY Obesity 5B81 Terminated [19]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cholecystokinin receptor (CCKR) TTKAPQ1 NOUNIPROTAC Antagonist [2]
Cholecystokinin receptor type A (CCKAR) TTCG0AL CCKAR_HUMAN Antagonist [3]
Neuropeptide Y receptor type 5 (NPY5R) TTY6EWA NPY5R_HUMAN Agonist [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 892).
2 Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic cancer cell lines. FEBS Lett. 1996 Apr 1;383(3):241-4.
3 Role of CCK(A) receptors in postprandial lower esophageal sphincter function in morbidly obese subjects. Dig Dis Sci. 2002 Nov;47(11):2531-7.
4 Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides. 2002 Aug;23(8):1485-90.
5 Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology. 2007 May;52(6):1396-402.
6 Clinical pipeline report, company report or official report of Shionogi (2011).
7 Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
8 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
9 Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.
10 Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue. J Med Chem. 1989 Feb;32(2):445-9.
11 Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung. 1987 Nov;37(11):1265-8.
12 A cholecystokinin-1 receptor agonist (CCK-8) mediates increased permeability of brain barriers to leptin. Br J Pharmacol. 2008 Jul;154(5):1009-15.
13 Melatonin as modulator of pancreatic enzyme secretion and pancreatoprotector. J Physiol Pharmacol. 2007 Dec;58 Suppl 6:65-80.
14 Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506.
15 Dual CCK-A and -B receptor antagonists (I) C9-methyl-1,4-benzodiazepines, Bioorg. Med. Chem. Lett. 7(2):169-174 (1997).
16 Obesity Pharmacotherapy: Current Perspectives and Future Directions. Curr Cardiol Rev. 2013 February; 9(1): 33-54.
17 US patent application no. 8,748,419, Antagonists.
18 Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. Jpn J Pharmacol. 1997 Feb;73(2):105-12.
19 CN patent application no. 102481276, Chemosensory receptor ligand-based therapies.